Steven Leonard Chapman Sells 6,816 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,816 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $93.13, for a total transaction of $634,774.08. Following the transaction, the chief executive officer now owns 227,710 shares in the company, valued at $21,206,632.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total transaction of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The stock was sold at an average price of $65.09, for a total transaction of $964,178.17.
• On Monday, January 22nd, Steven Leonard Chapman sold 1,958 shares of Natera stock. The shares were sold at an average price of $68.16, for a total transaction of $133,457.28.

Natera Price Performance

NTRA opened at $87.28 on Friday. The company has a fifty day simple moving average of $85.74 and a 200 day simple moving average of $65.57. The firm has a market cap of $10.54 billion, a price-to-earnings ratio of -23.03 and a beta of 1.37. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.09. The firm had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Equities research analysts expect that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Canaccord Genuity Group increased their price target on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research report on Friday, April 5th. Stephens reiterated an “overweight” rating and issued a $78.00 price target on shares of Natera in a research report on Tuesday, January 30th. Craig Hallum assumed coverage on shares of Natera in a research report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target on the stock. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. One investment analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.

Institutional Trading of Natera

Several hedge funds have recently bought and sold shares of NTRA. RiverPark Advisors LLC bought a new stake in Natera in the 4th quarter valued at about $27,000. Principal Securities Inc. bought a new stake in shares of Natera during the 4th quarter worth about $32,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Natera during the 3rd quarter worth about $44,000. Oliver Lagore Vanvalin Investment Group grew its stake in shares of Natera by 109.3% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after purchasing an additional 389 shares during the last quarter. Finally, CWM LLC grew its stake in shares of Natera by 224.4% in the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock worth $58,000 after purchasing an additional 911 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.